Market Cap 619.65M
Revenue (ttm) 84.28M
Net Income (ttm) -171.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -203.25%
Debt to Equity Ratio 13.72
Volume 1,944,800
Avg Vol 2,157,032
Day's Range N/A - N/A
Shares Out 99.30M
Stochastic %K 86%
Beta 0.98
Analysts Strong Sell
Price Target $27.33

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 771 9307
Address:
11682 El Camino Real, Suite 300, San Diego, United States
SonOfPaul19
SonOfPaul19 Aug. 18 at 10:05 PM
$SPRY Future SOC
0 · Reply
MrBean1234
MrBean1234 Aug. 18 at 12:38 PM
$SPRY https://seekingalpha.com/article/4937616-ars-pharmaceuticals-stock-reducing-costs-increasing-revenues-makes-buy Not the biggest of fan of Seeking Alpha but at least a good read explaining risk reward setup…just came out today
0 · Reply
DoreenElliott136
DoreenElliott136 Aug. 18 at 11:54 AM
$UAMY $GT $JACK $SPRY U.S. Antimony benefits from specialty-mineral demand, Goodyear remains tied to tire volumes and margins, Jack in the Box remains focused on restaurant traffic and franchise economics, and SPRY remains speculative. I'm watching commodity prices, auto demand, restaurant sales, and liquidity.
0 · Reply
foxhedgehog
foxhedgehog Aug. 17 at 8:00 PM
$SPRY I'll probably buy back into this, again. Even though I haven't done anything but lose money on it since I first saw that commercial lmao
1 · Reply
MrBean1234
MrBean1234 Aug. 17 at 7:49 PM
$SPRY glad I kept buying last week. Great day. Don’t let those gambling addicts on the Film board get to you. This is a unique opportunity to get very very rich over the next 18 months.
1 · Reply
ae1213
ae1213 Aug. 17 at 7:22 PM
$AQST $SPRY it is funny (and very shortsighted) how this board shows market cap obsession aqst vs. spry. I don’t think you have any idea what is ahead for this aqst and it’s deceiving management
2 · Reply
LTVI
LTVI Aug. 17 at 2:40 PM
1 · Reply
MrBean1234
MrBean1234 Aug. 17 at 2:31 PM
$SPRY trust in Donn Casale! Insane setup this !
0 · Reply
OracleofOntario
OracleofOntario Aug. 15 at 12:33 PM
$AQST with a yet to be approved product has nearly the same market cap as $SPRY. Not a good look for the SPRY management team.
2 · Reply
LTVI
LTVI Aug. 15 at 3:45 AM
$SPRY Q2 spending was ugly, but neffy itself is still growing. Revenue and market share increased, while several major institutions accumulated millions of shares. Now the key is simple: Can ARS keep growing sales while cutting expenses 40%+? If they can, the financial picture improves dramatically and the current valuation could look very different.
2 · Reply
Latest News on SPRY
ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c)

2026-08-16T14:10:24.000Z - 2 days ago

ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c)


ARS Pharmaceuticals sees cash flow break-even by end of 2027

2026-08-16T13:55:12.000Z - 2 days ago

ARS Pharmaceuticals sees cash flow break-even by end of 2027


ARS Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2026


ARS Pharmaceuticals Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

ARS Pharmaceuticals Earnings release: Q2 2026


ARS Pharmaceuticals Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

ARS Pharmaceuticals Quarterly report: Q2 2026


ARS Pharmaceuticals announces CEO succession

2026-07-07T20:50:12.000Z - 6 weeks ago

ARS Pharmaceuticals announces CEO succession

SNY


ARS Pharmaceuticals Announces CEO Succession

Jul 7, 2026, 4:30 PM EDT - 6 weeks ago

ARS Pharmaceuticals Announces CEO Succession


ARS Pharmaceuticals Provides Commercial and Financial Updates

Jun 24, 2026, 4:05 PM EDT - 7 weeks ago

ARS Pharmaceuticals Provides Commercial and Financial Updates


ARS Pharmaceuticals Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2026


ARS Pharmaceuticals Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Earnings release: Q1 2026


ARS Pharmaceuticals Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Quarterly report: Q1 2026


ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)

2026-05-15T10:07:53.000Z - 3 months ago

ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)


ARS Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing


ARS Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing


ARS Pharmaceuticals initiated with an Outperform at Northland

2026-04-09T11:14:32.000Z - 4 months ago

ARS Pharmaceuticals initiated with an Outperform at Northland


ARS Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 5 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2025


ARS Pharmaceuticals Annual report: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 5 months ago

ARS Pharmaceuticals Annual report: Q4 2025


ARS Pharmaceuticals Earnings release: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 5 months ago

ARS Pharmaceuticals Earnings release: Q4 2025


ARS Pharmaceuticals Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

ARS Pharmaceuticals Slides: Corporate presentation


ARS Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2025


ARS Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Quarterly report: Q3 2025


ARS Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Earnings release: Q3 2025


ARS Pharmaceuticals Slides: Q3 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Slides: Q3 2025


ARS Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2025


ARS Pharmaceuticals Quarterly report: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q2 2025


ARS Pharmaceuticals Earnings release: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q2 2025


ARS Pharmaceuticals Slides: Corporate Presentation

Jun 2, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Slides: Corporate Presentation


ARS Pharmaceuticals Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2025


ARS Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q1 2025


ARS Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q1 2025


ARS Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing


ARS Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing


ARS Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2024


ARS Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Annual report: Q4 2024


ARS Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q4 2024


SonOfPaul19
SonOfPaul19 Aug. 18 at 10:05 PM
$SPRY Future SOC
0 · Reply
MrBean1234
MrBean1234 Aug. 18 at 12:38 PM
$SPRY https://seekingalpha.com/article/4937616-ars-pharmaceuticals-stock-reducing-costs-increasing-revenues-makes-buy Not the biggest of fan of Seeking Alpha but at least a good read explaining risk reward setup…just came out today
0 · Reply
DoreenElliott136
DoreenElliott136 Aug. 18 at 11:54 AM
$UAMY $GT $JACK $SPRY U.S. Antimony benefits from specialty-mineral demand, Goodyear remains tied to tire volumes and margins, Jack in the Box remains focused on restaurant traffic and franchise economics, and SPRY remains speculative. I'm watching commodity prices, auto demand, restaurant sales, and liquidity.
0 · Reply
foxhedgehog
foxhedgehog Aug. 17 at 8:00 PM
$SPRY I'll probably buy back into this, again. Even though I haven't done anything but lose money on it since I first saw that commercial lmao
1 · Reply
MrBean1234
MrBean1234 Aug. 17 at 7:49 PM
$SPRY glad I kept buying last week. Great day. Don’t let those gambling addicts on the Film board get to you. This is a unique opportunity to get very very rich over the next 18 months.
1 · Reply
ae1213
ae1213 Aug. 17 at 7:22 PM
$AQST $SPRY it is funny (and very shortsighted) how this board shows market cap obsession aqst vs. spry. I don’t think you have any idea what is ahead for this aqst and it’s deceiving management
2 · Reply
LTVI
LTVI Aug. 17 at 2:40 PM
1 · Reply
MrBean1234
MrBean1234 Aug. 17 at 2:31 PM
$SPRY trust in Donn Casale! Insane setup this !
0 · Reply
OracleofOntario
OracleofOntario Aug. 15 at 12:33 PM
$AQST with a yet to be approved product has nearly the same market cap as $SPRY. Not a good look for the SPRY management team.
2 · Reply
LTVI
LTVI Aug. 15 at 3:45 AM
$SPRY Q2 spending was ugly, but neffy itself is still growing. Revenue and market share increased, while several major institutions accumulated millions of shares. Now the key is simple: Can ARS keep growing sales while cutting expenses 40%+? If they can, the financial picture improves dramatically and the current valuation could look very different.
2 · Reply
omega42
omega42 Aug. 15 at 12:41 AM
$SPRY this is what you've invested in (Q2 vs Q1 comparison).....one big cluster fuk
0 · Reply
BigGainTom
BigGainTom Aug. 14 at 7:14 PM
$AQST $SPRY Unless anything changes for either stock, looks like the market makers are not permitting AQST to have a higher market cap than SPRY. I assume AQST will stay under SPRY's market cap until they re-file the NDA and there is a high likelihood for approval.
3 · Reply
SonOfPaul19
SonOfPaul19 Aug. 14 at 6:36 PM
$SPRY Long and Strong here. Wish I had more ammo to load up. Smart money accumulating based on 13fs.
1 · Reply
LTVI
LTVI Aug. 14 at 3:36 PM
$SPRY @mikealfred is on the money. Shorting is a dangerous proposition! $NBIS $AQST
0 · Reply
ae1213
ae1213 Aug. 14 at 2:14 PM
$AQST $SPRY $AQST $SPRY hey Tomaz, I love the sp action in both aqst and spry. No more high cash burn and a clear path forward. I love aqst drop, no one cares about its market cap. Think twice before you post bk bs - your secret wish. It wouldn’t happen! There is a higher chance of aqst going under when they reach a commercial stage (if ever to their new PK data)
1 · Reply
MrBean1234
MrBean1234 Aug. 14 at 1:49 PM
$SPRY accumulating more and more thank you to the market gods 🙌…snatched some up in 5.20s
2 · Reply
ae1213
ae1213 Aug. 14 at 1:40 PM
$AQST $SPRY hey Tomaz, I love the sp action in both aqst and spry. No more high cash burn and a clear path forward. I love aqst drop, no one cares about its market cap. Think twice before you post bi bs - your secret wish.
0 · Reply
Jojimyung
Jojimyung Aug. 14 at 1:30 PM
$SPRY PBS approved in Australia. Seeing more patients prescribed / dispensed with Neffy, and given that majority don’t really use their adrenaline supply until the expiry, patients happy to try and switch to Neffy. I can imagine sales and revenue going up from here, since unlike Anaphylm already approved and has started marketing
1 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Aug. 14 at 1:29 PM
$SPRY This company appears to be down to just under 2.3 quarters of cash at current burn rate, while losing 💩 tons of money. They going to need a capital infusion soon... despite what CEO Donn Casale is saying.
2 · Reply
OnlyUp01
OnlyUp01 Aug. 14 at 1:12 PM
$SPRY Stock-Up bagholders it's only going downhill from here! Don't be a hero or you'll end up with zero!!!
0 · Reply
DonCorleone77
DonCorleone77 Aug. 14 at 1:06 PM
$SPRY $QNCX $AMAT $OTLK $SGML PRE-MARKET MOVERS: Currently Higher After Earnings: - Eton Pharmaceuticals (ETON) up 31.1% - Boost Run (BRUN) up 19.2% Currently Also Higher: - Reddit (RDDT) up 11.1% after being chosen for admission into the S&P 500 index - SanDisk (SNDK) up 7.2% after JPMorgan initiated coverage of the stock with an Overweight rating and $2,250 price target following the company's investor day meeting - Wayfair (W) up 3.6% after Bernstein upgraded shares to Outperform with a price target of $125, up from $100 - Fox Corp. (FOXA) up 2.9% after Wells Fargo upgraded the stock to Overweight with a price target of $80, up from $65 Currently Lower After Earnings: - ARS Pharmaceuticals (SPRY) down 14.6% - Quince Therapeutics (QNCX) down 1.8% - Applied Materials (AMAT) down 6.2% - Outlook Therapeutics (OTLK) down 5.7% - Sigma Lithium (SGML) down 4.7%.
0 · Reply